{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:41:02Z","timestamp":1792176062633,"version":"4.4.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["NeuroRehabilitation"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While there is strong evidence for botulinum toxin-A (BoNT-A) in post-stroke spasticity, there is a paucity of data in multiple sclerosis and other conditions in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Document the use of BoNT-A in the management of spasticity, with focus on the treatment of spasticity due to stroke and multiple sclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This noninterventional, retrospective study included all adults treated for upper and\/or lower limb spasticity (any etiology) at three centers in Italy who received \u22653 BoNT-A injection cycles between 2008 and 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Injection data from 149 patients were analyzed (n\u2009=\u200967 post-stroke, n\u2009=\u200947 MS, n\u2009=\u200935 other etiologies). The median treatment duration was 54.9 months in the post-stroke population and 41.9 months in the MS population. Total doses for the commercially available BoNT-A formulations were typically lower than approved for use in spasticity; we also observed clinically relevant differences in the muscle patterns treated between the MS and post-stroke indications. Regardless of etiology, most patients were satisfied with treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This retrospective study provides a snapshot of spasticity management for patients referred for BoNT-A treatment. Most patients were satisfied with their treatment over several cycles and the data support the effectiveness of BoNT-A for focal spasticity regardless of etiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay Summary<\/jats:title>\n                    <jats:p>While there is a lot of high-quality evidence supporting the efficacy (how well a medication works) and safety of botulinum toxin-A in treating spasticity, most of the research has been done in stroke survivors and there is a need to understand how botulinum toxin-A is used in people living with spasticity due to other causes.<\/jats:p>\n                    <jats:p>In this paper, a group of rehabilitation specialists from Italy describe a study where they reviewed the medical records of all patients who had received repeated botulinum toxin-A treatment for spasticity over a period of 10 years. They found that the two most common causes of the spasticity they treated were stroke and multiple sclerosis (MS). The authors made a number of important observations. Firstly, the doses of botulinum toxin used were typically on the lower end of the recommended dosing range in spasticity. Secondly, the way that stroke survivors and patients with MS are treated with botulinum toxin (e.g., the muscles injected) are different. Nevertheless, most patients said they were overall satisfied with repeated treatment and the findings support the use of botulinum toxin in managing spasticity in patients with a variety of conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10538135251329322","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:24:22Z","timestamp":1789136662000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, \u2018Real-world\u2019, Multicenter Study"],"prefix":"10.1177","volume":"57","author":[{"given":"Calogera","family":"Butera","sequence":"first","affiliation":[{"name":"Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Esposito","sequence":"additional","affiliation":[{"name":"U.O.C. of Neurophysiology, A.O.R.N. A. Cardarelli, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9413-3394","authenticated-orcid":false,"given":"Trinchillo","family":"Assunta","sequence":"additional","affiliation":[{"name":"Neurology Unit, San\u2019 Paolo Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Giovannelli","sequence":"additional","affiliation":[{"name":"Neurology Unit, Sant\u2019 Andrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rivaroli","sequence":"additional","affiliation":[{"name":"Ipsen, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pata","sequence":"additional","affiliation":[{"name":"Ipsen, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Beneteau","sequence":"additional","affiliation":[{"name":"Ipsen, Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia M","family":"Caglioni","sequence":"additional","affiliation":[{"name":"Ipsen, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-5412","authenticated-orcid":false,"given":"Ubaldo","family":"Del Carro","sequence":"additional","affiliation":[{"name":"Neurophysiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.540112"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15040280"},{"key":"e_1_3_5_4_1","unstructured":"Botox Summary of Product Characteristics (Italy). Available at: https:\/\/www.aifa.gov.it\/trova-farmaco"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2075263"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14100675"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14110"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-021-02312-4"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8304-z"},{"key":"e_1_3_5_10_1","unstructured":"Dysport Summary of Product Characteristics (Italy). https:\/\/www.aifa.gov.it\/trova-farmaco"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2017.02.014"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2340\/jrm.v55.4257"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20285"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10790268.2005.11754545"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-019-0991-2"},{"key":"e_1_3_5_16_1","volume-title":"Onabotulinum toxin A (Botox) for spasticity associated with multiple sclerosis [Internet]","author":"Hui D.","year":"2021","unstructured":"Hui D., Arg\u00e1ez C. (2021). Onabotulinum toxin A (Botox) for spasticity associated with multiple sclerosis [Internet]. Canadian Agency for Drugs and Technologies in Health. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571918\/"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00388"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3078-3"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12100646"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04392-8"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09638280400014576"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.2196\/17928"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2013.11.001"},{"key":"e_1_3_5_24_1","unstructured":"Royal College of Physicians (UK). (2018). Spasticity in adults: management using botulinum toxin. Available at https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/spasticity-adults-management-using-botulinum-toxin"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14110734"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002560"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.23736\/S1973-9087.17.04808-0"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-2801"},{"key":"e_1_3_5_29_1","unstructured":"Xeomin Summary of Product Characteristics (Italy). Available at: https:\/\/www.aifa.gov.it\/trova-farmaco"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.616097"}],"container-title":["NeuroRehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10538135251329322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10538135251329322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10538135251329322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:24:25Z","timestamp":1789136665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10538135251329322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/10538135251329322"],"URL":"https:\/\/doi.org\/10.1177\/10538135251329322","relation":{},"ISSN":["1053-8135","1878-6448"],"issn-type":[{"value":"1053-8135","type":"print"},{"value":"1878-6448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}